Pharming Group

Pharming Group ROE

The Return on Equity (ROE) of Pharming Group (PHARM.AS) as of Nov 16, 2026 is 1.07 %. In the previous year, Return on Equity (ROE) was -5.34 % — a change of -120.05% (higher).

ROE

1.07 %

YoY

-120.05%

Last updated:

In 2025, Pharming Group's return on equity (ROE) was 1.07 %, a -120.05% increase from the -5.34 % ROE in the previous year.

The Pharming Group ROE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROE
Date
ROE
Jan 1, 2018
40.47 USD
Jan 1, 2019
34.58 USD
Jan 1, 2020
20.54 USD
Jan 1, 2021
8.30 USD
Jan 1, 2022
6.68 USD
Jan 1, 2023
-4.93 USD
Jan 1, 2024
-5.34 USD
Jan 1, 2025
1.07 USD
The Pharming Group ROE history
YEARROEYoY
1.07 %-120.05%
-5.34 %+8.39%
-4.93 %-173.72%
6.68 %-19.50%
8.30 %-59.60%
20.54 %-40.58%
34.58 %-14.57%
40.47 %-109.52%
-425.26 %+566.09%
-63.84 %+52.85%
-41.77 %+116.14%
-19.32 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Pharming Group Stock analysis

What does Pharming Group do? Pharming Group NV was founded in 1988 and is headquartered in the Netherlands. The company specializes in the development and marketing of medical products for the treatment of rare diseases. Its business model is based on the discovery and development of recombinant proteins. These proteins are produced using genetic engineering techniques and serve as the foundation for the development of therapeutic products in various areas. The main focus of Pharming Group NV is the manufacturing and marketing of biopharmaceuticals. The company has a wide range of products used in the treatment of rare diseases, including C1-esterase inhibitor preparations used for acute attacks in hereditary angioedema. Another important product of Pharming Group NV is recombinant human lysozyme. It is used in the treatment of cystic fibrosis and has shown promising results as a therapeutic approach. Pharming Group NV also collaborates closely with various research and development organizations to develop new products and expand knowledge in the medical industry. The company has experienced impressive growth in recent years. In 2019, Pharming Group NV achieved a revenue of 149 million euros. A significant portion of this revenue was generated through the sale of C1-esterase inhibitor preparations. Pharming Group NV has also made a name for itself in the international market. The company has branches in the USA and Europe and works closely with international regulatory authorities to ensure smooth approval and marketing of its products. Overall, Pharming Group NV has a promising future as it continues to invest in research, development, and expansion of its product portfolio. By focusing on the development of products for the treatment of rare diseases, Pharming Group NV positions itself as a leading company in the medical industry and contributes to improving the lives of people worldwide. Pharming Group is one of the most popular companies on Eulerpool.

ROE Details

Decoding Pharming Group's Return on Equity (ROE)

Pharming Group's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Pharming Group's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Pharming Group's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Pharming Group’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Pharming Group stock

Return on Equity (ROE) of Pharming Group is 1.07 % in 2025.

Return on Equity (ROE) of Pharming Group changed from -5.34 % to 1.07 %, representing a -120.05% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) Pharming Group since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s Pharming Group with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Pharming Group

All Key Metrics — Pharming Group